Skip to main content
Premium Trial:

Request an Annual Quote

Early is Good Partners With Mayo Clinic on Prostate Cancer Test Development

NEW YORK — Diagnostics startup Early is Good (EIG) said on Tuesday that it has partnered with the Mayo Clinic on the development of a liquid biopsy test for advanced prostate cancer.

Under the terms of the deal, the partners will work on a multiomic test for metastatic castration-resistant prostate cancer. The Indianapolis-based company said the test could launch on its Multi-Omics Integration Platform, which is designed to simultaneously detect DNA, RNA, proteins, and small molecules in blood or urine without extraction or amplification.

Financial and other terms were not disclosed.

"Use of [multiomics] in metastatic prostate cancer can better inform clinicians about the nuances of the individual patient's cancer biology, which can significantly impact treatment decisions thus improving patient outcomes," Eric Kim, VP of clinical sciences at EIG, said in a statement. "As EIG's multiomic platform is not exclusive to prostate cancer, potential future collaborations will seek to include cancers of various organ systems, as well as stages of disease."

EIG, which raised $4 million in seed funding in late 2022, is also developing a laboratory-developed test called BCDx that is currently undergoing clinical validation for early bladder cancer detection.